BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma KW, Cheung TT. Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma. 2016;4:1-9. [PMID: 28097107 DOI: 10.2147/jhc.s96085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu L. Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy. Infect Agent Cancer 2020;15:8. [PMID: 32042307 DOI: 10.1186/s13027-020-0277-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Duan F, Wang YY, Xu DG, Shi J, Chen LY, Cui L, Bai YH, Xu Y, Yuan J, Chang C. Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(2): 153-160 [PMID: 30788041 DOI: 10.4251/wjgo.v11.i2.153] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
4 Wu Q, Liu TY, Hu BC, Li X, Wu YT, Sun XT, Jiang XW, Wang S, Qin XC, Ding HW, Zhao QC. CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. Front Oncol 2021;11:717626. [PMID: 34395292 DOI: 10.3389/fonc.2021.717626] [Reference Citation Analysis]
5 Sun J, Li Y, Wang Y, Liu Y, Liu Y, Wang X. Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study. Infect Agent Cancer 2018;13:17. [PMID: 29796061 DOI: 10.1186/s13027-018-0189-2] [Reference Citation Analysis]
6 Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, Ni Y. A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers (Basel) 2019;11:E1782. [PMID: 31766180 DOI: 10.3390/cancers11111782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
7 Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Maithel SK, Russell MC. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB (Oxford) 2021;23:422-33. [PMID: 32778389 DOI: 10.1016/j.hpb.2020.07.012] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Feng Y, Hao F. Hansenia weberbaueriana (Fedde ex H.Wolff) Pimenov & Kljuykov Extract Suppresses Proliferation of HepG2 Cells via the PTEN-PI3K-AKT Pathway Uncovered by Integrating Network Pharmacology and Iin Vitro Experiments. Front Pharmacol 2021;12:620897. [PMID: 33967754 DOI: 10.3389/fphar.2021.620897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kuo C, Wu H, Li C, Cata JP, Liu H, Hou M, Cherng Y, Tai Y. Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study. Medicina 2022;58:534. [DOI: 10.3390/medicina58040534] [Reference Citation Analysis]
10 Zhang P, Liu Q, Yuan M, Wang L. Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis. Infect Agent Cancer 2018;13:30. [PMID: 30181772 DOI: 10.1186/s13027-018-0203-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]